<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484130</url>
  </required_header>
  <id_info>
    <org_study_id>2018P000257</org_study_id>
    <nct_id>NCT03484130</nct_id>
  </id_info>
  <brief_title>Prospective Phenotyping of Autonomous Aldosterone Secretion</brief_title>
  <official_title>Prospective Phenotyping of Autonomous Aldosterone Secretion: A Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective cohort study will investigate the physiology and progression of autonomous&#xD;
      aldosterone secretion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary aldosteronism is a disorder wherein aldosterone is secreted by the adrenal gland(s)&#xD;
      independent of its physiologic regulators and cannot be appropriately suppressed with&#xD;
      sodium/volume loading. Primary aldosteronism is a common cause of hypertension and has a&#xD;
      relatively high prevalence. This is important since the excessive mineralocorticoid receptor&#xD;
      activation in primary aldosteronism contributes to adverse cardiovascular and renal outcomes&#xD;
      and death. For these reasons, it is critical that autonomous aldosteronism be detected early&#xD;
      in its course since appropriate treatment interventions may prevent cardiovascular disease.&#xD;
&#xD;
      In addition to severe and overt primary aldosteronism in hypertension, human studies have&#xD;
      shown that milder forms of primary aldosteronism can exist even among normotensive&#xD;
      individuals. Detailed physiologic studies have shown that normotensive individuals with a&#xD;
      phenotype of autonomous aldosterone secretion have greater cardiometabolic risk factors,&#xD;
      impaired renal-vascular function, and a higher risk for developing incident hypertension.&#xD;
      Further, older age is associated with greater autonomous aldosterone secretion, suggesting&#xD;
      that autonomous aldosterone secretion may progress over time. A better understanding of the&#xD;
      prevalence and progression of this type of &quot;subclinical&quot; autonomous aldosterone secretion may&#xD;
      inform our understanding of the pathogenesis of hypertension and cardiometabolic diseases.&#xD;
&#xD;
      This protocol is designed to be a prospective longitudinal study that will carefully&#xD;
      characterize the degree of autonomous aldosterone secretion among high-risk normotensive&#xD;
      individuals and follow them longitudinally with repeated phenotyping study visits to assess&#xD;
      the progression and severity of autonomous aldosterone secretion over time and its relevance&#xD;
      to cardiovascular health. Phenotyping visits will include measurements of the&#xD;
      renin-angiotensin-aldosterone system under controlled posture and variable sodium intakes and&#xD;
      repeated assessments of blood pressure.&#xD;
&#xD;
      This prospective cohort study will provide insights into normal and abnormal aldosterone&#xD;
      physiology over time and how it may contribute to time- or age-dependent hypertension and&#xD;
      cardiometabolic risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in renin</measure>
    <time_frame>5 years</time_frame>
    <description>The primary outcome is to evaluate the longitudinal change in plasma renin activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SASSI</measure>
    <time_frame>5 years</time_frame>
    <description>The longitudinal change in the sodium modulated suppression-to-stimulation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>5 years</time_frame>
    <description>Longitudinal changes in blood pressure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aldosterone Disorder</condition>
  <condition>Adrenal Gland Disease</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>High-Risk Normotensives</arm_group_label>
    <description>These high-risk normotensives are considered to be enriched for subclinical autonomous aldosterone secretion and have a high risk for developing incident hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium loaded diet</intervention_name>
    <description>At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The diet will consist of &gt;180 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.</description>
    <arm_group_label>High-Risk Normotensives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Restricted sodium diet</intervention_name>
    <description>At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium restricted diet. The diet will consist of &lt;40 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.</description>
    <arm_group_label>High-Risk Normotensives</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normotensive individuals who have a reasonably high risk of developing hypertension in the&#xD;
        next few years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 35-70 years&#xD;
&#xD;
          2. Systolic blood pressure of 120-135 mmHg and/or diastolic blood pressure of 75-85 mmHg&#xD;
&#xD;
          3. At least one, or more, of the following:&#xD;
&#xD;
               -  BMI ≥ 25 kg/m2&#xD;
&#xD;
               -  Family history of hypertension prior to the age of 60 years in a parent or&#xD;
                  sibling&#xD;
&#xD;
               -  Diabetes with a hemoglobin A1c &lt; 9%&#xD;
&#xD;
          4. If systolic blood pressure 115-135 mmHg and/or diastolic blood pressure 70-85 mmHg,&#xD;
             must have two or more of the following:&#xD;
&#xD;
               -  BMI ≥ 25 kg/m2&#xD;
&#xD;
               -  Family history of hypertension prior to the age of 60 years in a parent or&#xD;
                  sibling&#xD;
&#xD;
               -  Diabetes with a hemoglobin A1c &lt; 9%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of hypertension or use of antihypertensive medications&#xD;
&#xD;
          -  Known history of stroke, coronary artery disease, myocardial infarction, heart&#xD;
             failure, cerebral or aortic aneurysm, or preeclampsia.&#xD;
&#xD;
          -  Active cancer that is being treated with chemotherapeutic agents&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Daily use of prescribed opioid medications&#xD;
&#xD;
          -  Illicit drug use (cocaine, heroin, methamphetamine)&#xD;
&#xD;
          -  Daily non-steroidal anti-inflammatory medication use&#xD;
&#xD;
          -  Daily use of glucocorticoids&#xD;
&#xD;
          -  Electrocardiogram that shows evidence of prior myocardial infarction, atrial&#xD;
             arrhythmia, left or right bundle branch blocks.&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt; 60 mL/min/1.73m2&#xD;
&#xD;
          -  Active and untreated hyper- or hypo-thyroidism&#xD;
&#xD;
          -  Abnormal screening laboratories (comprehensive metabolic panel, complete blood count,&#xD;
             thyrotropin)&#xD;
&#xD;
          -  BMI ≥ 45 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand Vaidya, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anand Vaidya, MD, MMSc</last_name>
    <phone>6175258285</phone>
    <email>anandvaidya@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Marion, NP</last_name>
    <phone>6177325186</phone>
    <email>kmarion@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Vaidya, MD, MMSc</last_name>
      <phone>617-525-8285</phone>
      <email>anandvaidya@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Marion, NP</last_name>
      <phone>6177325186</phone>
      <email>kmarion@partners.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>September 6, 2020</last_update_submitted>
  <last_update_submitted_qc>September 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Anand Vaidya</investigator_full_name>
    <investigator_title>Director, Center for Adrenal Disorders</investigator_title>
  </responsible_party>
  <keyword>primary aldosteronism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Gland Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

